Oncotelic Therapeutics, Inc. — Income Charts
12 years of history · ending 2023-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$70K
R&D↓-95.5% -$1M
$61K
D&A↓-62.4% -$21K
$13K
Operating Income↓-54.2% -$2M
$-7M
EBITDA↓-54.5% -$2M
$-7M
Interest Expense↑+39.4% +$295K
$1M
Interest Income↓-99.5% -$27K
$123
Other Income/Expense
—
Pretax Income
—
Tax Provision
$5K
Net Income↓-19.1% -$1M
$-8M
Operating Margin
-9497.2%
Net Margin
-11290.1%
Effective Tax Rate
—
Deferred Tax Assets
$65M
Deferred Tax Liabilities
—
DTA Valuation Allowance↑+20388.4% +$13M
$13M
NOL Carryforwards↑+17796.3% +$10M
$10M
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↓-13.0pts
21.0%
ETR State + Local (pp)↓-0.7pts
-0.7%
Operating Lease Cost↓-83.0% -$174K
$36K
Revenue YoY Variation
-39.1%
Income YoY Variation↑+536.4pts
31.6%